Iptacopan for treating complement 3 glomerulopathy

Iptacopan is in development for the treatment of patients with complement 3 glomerulopathy (C3G) which is a rare disease. C3 is a blood protein that plays a key role in the normal immunity. The damaging build-up of the C3 protein in kidneys of patients with C3 glomerulopathy mostly results from dysregulation of the alternative complement pathway which is part of the body’s immune system. The build-up of this C3 protein damages the kidneys and can lead to a life-threatening condition which prevents the kidneys from filtering fluids and waste products from the body.